Exercise of Share Options & Total Voting Rights
21 August 2024
Idox plc
("Idox" or "Group" or "Company")
Exercise of Share Options &
Total Voting Rights
Idox plc (AIM: IDOX), a leading supplier of specialist information management software and geospatial data solutions to the public and asset-intensive sectors, announces that it has issued 13,192 new ordinary shares of 1 pence each in the Company ("Ordinary Shares") pursuant to an exercise of options by an employee under its Idox plc Long Term Incentive Plans.
An application has been made for the 13,192 new Ordinary Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will occur at 8.00 a.m. on or around 27 August 2024.
The Company holds no ordinary shares in treasury. The total number of ordinary shares in issue following Admission will be 460,182,046. Therefore, the total number of ordinary shares with voting rights in the Company will be 460,182,046.
The above figure of 460,182,046 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
For further information please contact:
Idox plc | +44 (0) 870 333 7101 |
Chris Stone, Non-Executive Chairman | |
David Meaden, Chief Executive |
|
Anoop Kang, Chief Financial Officer |
|
| |
Peel Hunt LLP (NOMAD and Broker) | +44 (0) 20 7418 8900 |
Benjamin Cryer |
|
Adam Telling |
|
| |
MHP | + 44 (0) 20 3128 8100 |
Reg Hoare | |
Ollie Hoare | |
Matthew Taylor |
About Idox plc
For more information see www.idoxplc.com @Idoxgroup
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.